PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 142 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.34 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $41,430,000 | +105859.1% | 1,500,000 | -11.8% | 2.32% | -9.9% |
| Q1 2023 | $39,100 | -98.5% | 1,700,000 | +344.9% | 2.58% | +1255.3% |
| Q2 2018 | $2,568,000 | -21.8% | 382,139 | 0.0% | 0.19% | -22.4% |
| Q1 2018 | $3,283,000 | -60.5% | 382,139 | -4.5% | 0.24% | -71.9% |
| Q4 2017 | $8,320,000 | -5.8% | 400,000 | -20.0% | 0.87% | -44.2% |
| Q3 2017 | $8,835,000 | +56.2% | 500,000 | 0.0% | 1.56% | +66.5% |
| Q2 2017 | $5,655,000 | -35.4% | 500,000 | -26.9% | 0.94% | -26.3% |
| Q1 2017 | $8,757,000 | -44.7% | 683,600 | -5.1% | 1.27% | -40.4% |
| Q4 2016 | $15,833,000 | -6.3% | 720,000 | -10.0% | 2.13% | +14.5% |
| Q3 2016 | $16,904,000 | – | 800,000 | – | 1.86% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $43,400,000 | 3.81% |
| BVF INC/IL | 3,901,759 | $69,139,000 | 2.70% |
| COMMODORE CAPITAL LP | 498,079 | $8,826,000 | 2.33% |
| Altium Capital Management LP | 346,000 | $6,131,000 | 1.61% |
| Twin Lakes Capital Management, LLC | 139,287 | $2,468,000 | 1.45% |
| Opaleye Management Inc. | 330,222 | $5,852,000 | 1.09% |
| EcoR1 Capital, LLC | 1,443,800 | $25,584,000 | 0.89% |
| OBERMEYER WOOD INVESTMENT COUNSEL, LLLP | 776,689 | $13,763,000 | 0.76% |
| JABODON PT CO | 90,656 | $1,606,000 | 0.66% |
| Artal Group S.A. | 1,500,000 | $26,580,000 | 0.60% |